Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Bortezomib for maintenance, consolidation ups survival in multiple myeloma

26 Apr 2020

Bortezomib-based consolidation and maintenance therapies for multiple myeloma improve survival but come with safety concerns, reports a recent meta-analysis.

Accessing the databases of Embase, Web of Science and PubMed, researchers retrieved ten randomized controlled trials (n=3,147), in which bortezomib-containing regimens were compared to other treatments or to observation. Outcomes included progression-free (PFS) and overall (OS) survival, as well as the occurrence of adverse events.

Bortezomib-based maintenance therapies showed significant efficacy in boosting PFS (hazard ratio [HR], 0.72, 95 percent confidence interval [CI], 0.55–0.95; p=0.02) and OS (HR, 0.71, 95 percent CI, 0.58–0.87; p=0.001). Excluding transplant-ineligible patients attenuated the effect on PFS, but only slightly (HR, 0.94, 95 percent CI, 0.699–1.001; p=0.052). The benefit on OS remained significant (HR, 0.72, 95 percent CI, 0.54–0.96; p=0.025).

In comparison, bortezomib-based consolidation therapies improved only PFS (HR, 0.77, 95 percent CI, 0.68–0.88; p<0.001) but not OS (HR, 0.98, 95 percent CI, 0.78–1.24; p=0.87). Excluding one study did not change this.

In terms of safety, researchers also found that bortezomib-containing consolidation and maintenance therapies came with a higher risk of grade 3 neurologic symptoms that was of borderline significance (risk ratio [RR], 1.59, 95 percent CI, 0.94–2.69; p=0.08).

There were also nonsignificant increases in the likelihood of developing gastrointestinal symptoms (RR, 1.66, 95 percent CI, 0.71–3.88; p=0.24) and fatigue (RR, 2.10, 95 percent CI, 0.83–5.30; p=0.12).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.